伊人久久大香线蕉AV影院,情侣国产一二三区视频观看,香蕉丝瓜榴莲在线观看√天堂资源中文官网,日韩精品无码观看视频免费,亚洲伊人成无码综合网欧美亚洲综合在线一区,国产午夜精品视频一区二区三区,亚洲毛片在线日韩无码大乱交,国产精品国产三级欧美二区

First China-made Anti-ST2 Antibody Developed by Mabwell Approved for Clinical Study

Release time:May 08, 2021

May 8, 2021, Shanghai— Mabwell Bioscience Co., Ltd. ("Mabwell") announced today that its application for conducting the clinical trial of its product Anti-ST2 Antibody Injection (9MW1911) was formally approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration. The approved indications include asthma and chronic obstructive pulmonary disease. 9MW1911 Injection is the first China-made antibody directed against the target of ST2 that has been authorized by China NMPA to conduct clinical trials in China.

It is an innovative humanized monoclonal antibody drug independently developed by Mabwell, a doemstic pharmaceutical company in China. The drug’s antibody molecule is derived based on the B-lymphocyte screening platform, and the product is characterized by higher binding affinity and potent biological activity. Nonclinical studies have shown that the in vivo mechanism of action of this product in animals was definite and clear. After binding specifically to the target ST2, it blocks the activation of ST2-mediated signaling pathway induced by cytokine IL-33, hence inhibiting the inflammatory reactions and achieving therapeutic effects in multiple auto-immune diseases.

Currently, Mabwell has completed the establishment of molecular discovery and druggability investigation system, process development and quality study system and production transformation system. Its comprehensive R&D pipelines have covered more than 10 novel drug varieties in various therapeutic fields such as auto-immune diseases, tumor, metabolic disorders, ophthalmologic diseases and infections. Of these, one variety has been applied for manufacturing and 4 varieties have entered into the stage of critical registration application for clinical trials. In the near future, the synergistic advantages between the company's various platforms will be further exerted to accelerate the development of new drug molecules within the R&D pipelines and expedite the overall process of related clinical trials.

色噜噜综合亚洲AV中文无码| 少妇激情无码av一区二区| 国产伦精品一区二区三区| 亚亚洲国产精品va在线观看香蕉| 久久人人爽天天玩人人妻精品| 中文字幕无码亚洲字幕成a人蜜桃| 无码专区无码专区视频网址| 一级特黄AAA大片在线观看| 五月精品亚洲婷婷| 国产性猛交╳xxx乱大交| 可以直接进入网站的正能量视频,一级a视频| 欧美va国产va在线观看| 韩日午夜在线资源一区二区| 色一情一乱一伦一区二区三区日本| 國產SM重味一區二區三區| 人妻少妇乱子伦无码视频专区| 综合亚洲伊人午夜网| 国产91色综合久久免费分享| 光棍影院一级毛片视频| 奇米777狠狠色嚕嚕狠狠狠| 国产精品日本亚洲777| 亚洲高清无码一二三区A片| 久久国产亚洲日韩一本| 久久麻豆精亚洲AV品国产| 91精品国产日韩91久久久久久无码乱码| 成人va在线一区二区三区四区| 中文字幕人妻av一区二区| 国产精品无码无卡无需播放器| 国产精品偷伦视频| 丁香花在线影院观看在线播放| 国产毛片一区亚洲s色大片| 欧洲亚洲另类一区在线观看| 四虎成人永久在线精品免费| 久久国产亚洲欧美久久| 亚洲欧洲日韩国产AⅤ在线| 伊人久久大线蕉色首页| 欧美精品成人久久网站| 国产精品女人精品久久久天天| 亚洲精品无码久久下载| 亚洲精品aⅤ无码精品| 无套内谢的新婚少妇国语播放|